Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

被引：0
|
作者：
Alex Diamantopoulos
A. Finckh
T. Huizinga
D. K. Sungher
L. Sawyer
D. Neto
F. Dejonckheere
机构：
[1] Symmetron Limited,Rheumatology
[2] Kinetic Centre,Rheumatology
[3] University Hospitals of Geneva,undefined
[4] Leiden University Medical Center,undefined
[5] F. Hoffmann-La Roche,undefined
来源：
PharmacoEconomics | 2014年 / 32卷
关键词：
Palliative Care; Juvenile Idiopathic Arthritis; Tocilizumab; Visual Analogue Scale Pain; Health Assessment Questionnaire;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 787
页数：12
相关论文
共 50 条
  • [31] Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis.
    Carlson, Josh J.
    Ogale, Sarika
    Dejonckheere, Fred
    Sullivan, Sean
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1037 - S1038
  • [32] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR
    Albuja, M. F.
    Torres, F. G.
    Mould, J.
    Estevez, C.
    VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [33] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
    Guijarro, P.
    Crespo, C.
    Brosa, M.
    VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [34] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) TREATMENT IN TURKEY
    Erdogan-Ciftci, E.
    Yanik, L.
    Saka, O.
    VALUE IN HEALTH, 2019, 22 : S699 - S700
  • [35] COST-EFFECTIVENESS OF SECUKINUMAB FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN THE UK
    Kirkham, B.
    Buchanan, V
    Sullivan, W.
    Graham, C. N.
    Miles, L.
    Jugl, S. M.
    Gunda, P.
    Halliday, A.
    VALUE IN HEALTH, 2017, 20 (09) : A536 - A536
  • [36] Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice
    Virkki, L. M.
    Konttinen, Y. T.
    Peltomaa, R.
    Suontama, K.
    Saario, R.
    Immonen, K.
    Jantti, J.
    Tuomiranta, T.
    Nykanen, P.
    Hameenkorpi, R.
    Heikkila, S.
    Isomaki, P.
    Nordstrom, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (06) : 1059 - 1066
  • [37] The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
    Joensuu, Jaana T.
    Huoponen, Saara
    Aaltonen, Kalle J.
    Konttinen, Yrjo T.
    Nordstrom, Dan
    Blom, Marja
    PLOS ONE, 2015, 10 (03):
  • [38] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
  • [39] Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy
    De, VS
    Giuliani, G
    Diamantopoulos, A
    Brown, B
    Kielhorn, A
    VALUE IN HEALTH, 2006, 9 (03) : A26 - A26
  • [40] THE COST-EFFECTIVENESS OF BIOLOGIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW
    Joensuu, J. T.
    Aaltonen, K. J.
    Huoponen, S.
    Konttinen, Y. T.
    Nordstrom, D.
    Blom, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 451 - 452
12345